Certara, Inc. (CERT) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of Certara, Inc. and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CERT
Certara, Inc.
$9.27HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.47HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CERT vs RARE
growth of $100 · dividends reinvested · last 6yCERT -73.6% (-19.9%/yr)RARE -89.2% (-31.0%/yr)CERT compounded faster over this window
CERT RARE
CERT vs RARE: by the numbers
- •CERT is the larger company ($1.44B vs $1.43B market cap).
- •Both run net losses; CERT's is the smaller (-16.75% vs -81.79% net margin).
- •RARE grew revenue faster over the past five years (14.81% vs 9.31% CAGR).
Metrics side by side
Valuation
| Metric | CERT | RARE |
|---|---|---|
| Forward P/E | 27.22 | N/A |
| P/S ratio | 3.53 | 1.99 |
| P/B ratio | 1.49 | N/A |
| EV / EBITDA | 26.24 | N/A |
| FCF yield | 4.27% | N/A |
Profitability
| Metric | CERT | RARE |
|---|---|---|
| Gross margin | 58.33% | 83.12% |
| Operating margin | 1.86% | -73.77% |
| Net margin | -16.75% | -81.79% |
| ROE | -7.08% | N/A |
| ROIC | 0.59% | -53.48% |
Growth (annualized)
| Metric | CERT | RARE |
|---|---|---|
| Revenue CAGR (5Y) | 9.31% | 14.81% |
| FCF CAGR (5Y) | 8.78% | N/A |
| Total return CAGR (5Y) | -21.31% | -30.14% |
Frequently asked
- Which has grown faster, CERT or RARE?
- Over the past five years, RARE grew revenue faster — CERT at a 9.31% CAGR versus RARE at 14.81%.
- How have CERT and RARE total returns compared?
- Over the past 5 years, CERT delivered -21.31% and RARE delivered -30.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Certara ROEUltragenyx Pharmaceutical ROECertara operating marginUltragenyx Pharmaceutical operating marginCertara revenue growthUltragenyx Pharmaceutical revenue growthCertara free cash flowUltragenyx Pharmaceutical free cash flow
Certara & Ultragenyx Pharmaceutical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.